These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2889606)

  • 1. Hypothermia and poikilothermia induced by a kappa-agonist opioid and a neuroleptic.
    Adler MW; Geller EB
    Eur J Pharmacol; 1987 Aug; 140(2):233-7. PubMed ID: 2889606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of hypothermia in the guinea pig by a kappa-agonist opioid alone and in combination with chlorpromazine.
    Adler MW; Bradley E; Martinez R; Geller EB
    Pharmacol Biochem Behav; 1991 Sep; 40(1):129-32. PubMed ID: 1664107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
    Milanés MV; Vargas ML; Martín MI
    Eur J Pharmacol; 1994 Dec; 271(1):103-9. PubMed ID: 7698193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
    Vonvoigtlander PF; Lahti RA; Ludens JH
    J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
    Czlonkowski A; Millan MJ; Herz A
    Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
    [No Abstract]   [Full Text] [Related]  

  • 6. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.
    Iyengar S; Kim HS; Wood PL
    J Pharmacol Exp Ther; 1986 Aug; 238(2):429-36. PubMed ID: 3016237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of kappa receptor agonists with Ca2+ channel antagonists in the modulation of hypothermia.
    Pillai NP; Ross DH
    Eur J Pharmacol; 1986 Dec; 132(2-3):237-44. PubMed ID: 3028838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level.
    Alcaraz C; Milanés MV; Vargas ML
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1385-9. PubMed ID: 8396634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertussis and cholera toxins modulate kappa-opioid receptor agonists-induced hypothermia and gut inhibition.
    Shukla VK; Turndorf H; Bansinath M
    Eur J Pharmacol; 1995 Mar; 292(3-4):293-9. PubMed ID: 7796869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
    Fukagawa Y; Katz JL; Suzuki T
    Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
    Pugsley MK; Penz WP; Walker MJ; Wong TM
    Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary-adrenocortical response to acute and chronic administration of U-50,488H in the rat.
    Milanés MV; Gonzalvez ML; Fuente T; Vargas ML
    Neuropeptides; 1991 Oct; 20(2):95-102. PubMed ID: 1665898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
    Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
    J Pharmacol Exp Ther; 1996 May; 277(2):877-84. PubMed ID: 8627570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal antinociceptive actions and naloxone reversibility of intravenous mu- and kappa-opioids in spinalized rats: potency mismatch with values reported for spinal administration.
    Parsons CG; West DC; Headley PM
    Br J Pharmacol; 1989 Oct; 98(2):533-43. PubMed ID: 2555012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T; Ohno M; Ueki S
    Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The kappa agonists PD117302 and U50488 produce a biphasic effect on 24 hour food intake in the rat.
    Hewson G; Hill RG; Hughes J; Leighton GE; Turner WD
    Neuropharmacology; 1987 Nov; 26(11):1581-4. PubMed ID: 2829048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.
    Iyengar S; Kim HS; Wood PL
    Brain Res; 1987 Dec; 435(1-2):220-6. PubMed ID: 2892574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive effects of mu- and kappa-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism.
    Stein C; Millan MJ; Yassouridis A; Herz A
    Eur J Pharmacol; 1988 Oct; 155(3):255-64. PubMed ID: 2853065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
    Bhargava HN; Ramarao P; Gulati A
    Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.